Skip to main content
. Author manuscript; available in PMC: 2014 May 13.
Published in final edited form as: Invest Ophthalmol Vis Sci. 2008 May 16;49(9):4018–4025. doi: 10.1167/iovs.08-1914

Figure 2.

Figure 2

Flow cytometry results showing percentages of FITC–Gr-1+ neutrophils in the peripheral blood of Gr-1 antibody– (A) and control antibody–treated (B) mice at day 5 pi. Efficacy of systemic depletion of Gr-1+ neutrophils in Gr-1 antibody– and control antibody–treated mice at day 5 pi (C). The percentages of FITC–Gr-1+ neutrophils in cells derived from the whole eyes of HSV-1–inoculated Gr-1 antibody– (D) and control antibody–treated (E) mice at day 5 pi. The efficacy of depletion of Gr-1+ neutrophils in the eye-derived cells of Gr-1 antibody– and control antibody–treated mice at day 5 pi (F).